Visão geral da empresa
A company operates as a clinical-stage biopharmaceutical entity dedicated to developing novel disease-modifying therapies specifically for immunology and inflammatory diseases, with a distinct strategic focus on chronic fibrotic indications characterized by significant unmet medical needs. AgomAb Therapeutics NV functions within the healthcare sector, specifically the biotechnology industry, which typically involves high research and development expenditures before products reach commercialization. The company's current valuation is represented by a market capitalization of $502.53M, while its annual revenue for the trailing twelve months is not available, and the organization employs a workforce of 57 individuals. These financial and operational metrics indicate that the company is in a pre-revenue or early-stage commercialization phase, where the market cap reflects investor sentiment regarding the potential of the clinical pipeline rather than current cash flow generation or established sales volumes typical of mature pharmaceutical firms.
Saúde financeira
The financial performance of the entity is characterized by a revenue figure marked as not available for the trailing twelve months, a net income loss of $-72,265,000, and an EBITDA of $-54,430,000. The substantial gap between the non-existent revenue and the significant net income loss of $-72,265,000 reveals a cost structure dominated by research and development expenses and operational overheads that have not yet been offset by sales income. The free cash flow is listed as not available, which implies that the company has not yet generated positive cash flow from operations sufficient to cover its capital expenditures, limiting its immediate financial flexibility to rely primarily on existing cash reserves or external financing. All three margin metrics—the gross margin, operating margin, and profit margin—are reported at 0.0%, indicating that the company has not yet achieved profitability from its operations or sales, a common characteristic for clinical-stage biotechs prior to product approval. Regarding balance sheet liquidity, the company holds cash of $171.46M against a total debt of $1.54M, resulting in a debt-to-equity ratio of 0.82, which suggests a balance sheet that is heavily weighted towards cash assets rather than leveraged debt obligations. The current ratio stands at 13.99, a figure that indicates an exceptionally strong position regarding short-term liquidity, as the company possesses current assets significantly exceeding its current liabilities. Furthermore, return on equity and return on assets are both listed as not available, meaning that these return metrics cannot be calculated due to the lack of net income or the specific accounting definitions applied to the entity's current financial stage.
Avaliação de valorização
The valuation metrics for AgomAb Therapeutics NV include a P/E Ratio (TTM) that is not available and a forward P/E of -5.47, implying that the market is pricing in future earnings potential rather than trailing profitability, as the negative forward multiple suggests expectations of continued losses or earnings not yet realized. The price-to-book ratio is recorded as -0.00, which indicates that the market price is not a meaningful premium over book value in the traditional sense, often seen in companies with intangible assets or negative equity adjustments in their accounting. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and an EV/EBITDA of -2.39, suggest that traditional earnings-based valuation models are not applicable, and investors must rely on pipeline potential and cash runway instead. The stock's price volatility range is defined by a 52-week high of $17.45 and a 52-week low of $9.00. To determine the current position relative to this range, one must calculate the percentage distance from these bounds, noting that the stock has experienced significant fluctuation within this specific band of $8.45 over the last year. The beta value is not available, which means there is no data provided to explain the stock's price volatility relative to the broader market movements during this period.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue in a historical context. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, indicating that the company retains all earnings or cash reserves to reinvest into its development pipeline rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage biotechs, where capital is directed toward advancing Ontunisertib and other assets in the product pipeline to secure regulatory approval and future commercialization. Consequently, the overall growth and income profile is defined by a reliance on capital appreciation driven by clinical trial milestones rather than current dividend income or historical earnings growth rates.